Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

Akira Kubota1*, Hajime Maeda1, Akira Kanamori1, Kiyokazu Matoba1, Yasuyuki Jin1, Fuyuki Minagawa1, Mitsuo Obana1, Kotaro Iemitsu1, Shogo Ito1, Hikaru Amamiya1, Mizuki Kaneshiro1, Masahiko Takai1, Hideaki Kaneshige1, Kazuhiko Hoshino1, Masashi Ishikawa1, Nobuaki Minami1, Tetsuro Takuma1, Nobuo Sasai1, Sachio Aoyagi1, Takehiro Kawata1, Atsuko Mokubo1, Hiroshi Takeda1, Shin Honda1, Hideo Machimura1, Tetsuya Motomiya1, Manabu Waseda1, Yoshikazu Naka1, Yasushi Tanaka2, Yasuo Terauchi3, Ikuro Matsuba1

ABSTRACT

Aims/Introduction: To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months’ therapy.

Materials and Methods: A retrospective, observational study of 741 type 2 diabetes patients was carried out; 110 received sitagliptin monotherapy, and 631 received combination therapy with sitagliptin when other oral medications were insufficient. The primary outcome measure was glycated hemoglobin (HbA1c) measured at 0, 4 and 12 weeks of sitagliptin therapy.

Results: In the monotherapy and combination therapy groups, HbA1c decreased significantly after 12 weeks. Target HbA1c (<7%) was achieved in 39.1% overall. On logistic regression analysis, baseline HbA1c was the strongest contributing factor for achieving target HbA1c; baseline body mass index and duration of diabetes were also significant factors. A total of 82 patients (11%) were unresponsive to sitagliptin. These patients’ baseline body mass index was significantly higher and their baseline HbA1c was significantly lower than those of patients who responded to sitagliptin. The most commonly co-administered drugs were sulfonylureas (508 patients). In these patients, the dose of sulfonylurea decreased with time. In 66 patients whose sulfonylurea dosage was reduced when sitagliptin was started, HbA1c and bodyweight decreased significantly after 12 weeks. A total of 24 patients receiving sulfonylureas had mild hypoglycemia, but none discontinued sitagliptin.

Conclusions: Sitagliptin was effective and safe as both monotherapy and combination therapy in Japanese type 2 diabetes patients. When sulfonylureas were ineffective, sitagliptin improved glycemic control. In patients whose sulfonylurea dose was reduced at the start of sitagliptin, blood glucose improved and bodyweight decreased after 12 weeks. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00221.x, 2012)

KEY WORDS: Diabetes mellitus, Sitagliptin, Sulfonylurea

INTRODUCTION

Dipeptidyl peptidase-4 (DPP-4) inhibitors belong to a novel class of antidiabetic agents that increase the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)1–5. Sitagliptin is the first DPP-4 inhibitor in Japan, where it has been available for approximately 2 years. The oral diabetes drugs that were available for clinical use before this were sulfonylureas, biguanides, thiazolidines, α-glucosidase inhibitors (αGI) and glinides. However, blood glucose cannot actually be well controlled in many type 2 diabetes patients with these drugs, and improved glycemic control in a greater number of diabetic patients is anticipated with sitagliptin, given its novel mechanism of action.

Japanese people have genetically low insulin secretory capacity6–8, and sulfonylurea drugs are the most commonly used drug therapy for type 2 diabetes9. In monotherapy, sitagliptin is expected to be effective for a wide range of diabetes patients10,11, as well as cases of secondary sulfonylurea failure, but there are currently no reported results on the efficacy and safety of sitagliptin in large numbers of patients in actual clinical practice. The study group of the diabetes committee has carried out several observational studies in Kanagawa, such as looking at the prevalence of diabetic complications (neuropathy12 and nephropathy). Our committee carried out a retrospective,
observational study of sitagliptin, which was given to type 2 diabetes patients in the community by the diabetes specialists of our committee. A large-scale analysis of the efficacy and safety of sitagliptin monotherapy and combination therapy for 12 weeks in actual clinical practice, in which the primary outcome was glycated hemoglobin (HbA1c), is reported.

MATERIALS AND METHODS

The survey participants were type 2 diabetes patients receiving outpatient treatment at 28 hospitals or clinics specializing in diabetes belonging to the Diabetes Committee of the Kanagawa Physicians Association from December 2009 to August 2010. Oral consent for participation in the present study was obtained from type 2 diabetes patients who were using diet and exercise therapy, and from patients with insufficient glycemic control despite the use of hypoglycemic agents. Sitagliptin monotherapy or sitagliptin in addition to other drugs was then given, starting at a dose of 25 mg or 50 mg. If good glycemic control was not obtained after this, the sitagliptin dose could be increased to 100 mg. The total number of registered patients was 741 (Figure 1). The monotherapy group (n = 110) enrolled drug-naive patients who were given sitagliptin when glycemic control was inadequate on diet and exercise therapy, and the combination therapy group (n = 631) enrolled patients who were given sitagliptin in addition to the previously prescribed medications when other oral medications were insufficient. In order to evaluate the efficacy of sitagliptin without the effects of discontinuation of conventional drugs, those in whom one or more conventional antidiabetes drugs were discontinued at the start of sitagliptin were not enrolled. The present study was an observational study that aimed to evaluate the efficacy and adverse events of sitagliptin, and approval was obtained from the Ethics Review Board of the Kanagawa Physicians Association.

Outcome Measures

The patients' baseline characteristics were as follows: monotherapy group, n = 110 (64 men, 46 women), mean age 63.4 ± 11.8 years, duration of diabetes 8.2 ± 6.4 years and body mass index (BMI) 23.84 ± 4.36 kg/m²; and combination therapy group n = 631 (360 men, 271 women), mean age 63.4 ± 11.2 years, duration of diabetes 12.8 ± 8.2 years and BMI 24.85 ± 4.35 kg/m². In these combined 741 patients (424 men, 317 women, mean age 63.4 ± 11.3 years, duration of diabetes 12.1 ± 8.1 years, BMI 24.70 ± 4.37 kg/m²), HbA1c, the primary outcome measure, was measured at the start, and after 4 and 12 weeks of sitagliptin therapy. Bodyweight was also measured at the start and after 12 weeks. HbA1c, expressed in National Glycohemoglobin Standardization Program (NGSP) units-equivalent value, was measured by high-performance liquid chromatography.

Co-administered drugs in the combination therapy group were analyzed (Figure 1), and the numbers of patients taking sulfonylureas, biguanides, pioglitazone, αGI and glinides were 508, 379, 179, 73 and 37, respectively. Of 508 patients (297 men, 211 women, mean age 64.3 ± 10.7 years, duration of diabetes 13.8 ± 8.2 years, BMI 24.50 ± 4.30 kg/m²) using sulfonylureas, the dose of sulfonylurea was reduced at the start of sitagliptin in 66 patients and not reduced in 442 patients. In both the reduced and non-reduced sulfonylurea dose groups, HbA1c was analyzed at baseline and after 4 and 12 weeks, and bodyweight was analyzed at baseline and after 12 weeks.

To identify factors contributing to the achievement of HbA1c <7.0% and factors contributing to responsiveness to sitagliptin treatment after administration of sitagliptin for 12 weeks, logistic regression analyses were carried out for age at baseline, sex, duration of diabetes, baseline BMI, baseline HbA1c and whether HbA1c <7.0% was reached after 12 weeks or whether HbA1c after 12 weeks was decreased from the baseline value. Unresponsiveness to sitagliptin treatment was defined as HbA1c after 12 weeks equal to or higher than baseline HbA1c.

Statistical Analysis

All analyses were carried out using SPSS version 19 for Windows (SPSS, Chicago, IL, USA). For bodyweight, data were analyzed by paired t-tests. For HbA1c data were analyzed by one-way ANOVA. Statistical analysis comparing the baseline characteristics of the responsive and unresponsive groups was carried out using the Mann–Whitney U-test. Data are presented as means ± SD. A P-value < 0.05 was considered significant.

RESULTS

The analysis included 741 patients, 110 patients who received sitagliptin monotherapy and 631 patients who received combination therapy. Most patients in the combination therapy group had either two co-administered drugs (33.9%) or one
co-administered drug (33.6%), followed by three (15.5%) and four co-administered drugs (2.2%). The most common co-administered drugs were sulfonylureas (80.5% of the combination therapy group). More than half (60.1%) also used biguanides, followed by pioglitazone (28.4%), αGI (11.6%) and glinides (5.9%). In the monotherapy and combination therapy groups, HbA1c was 7.88 ± 1.54% and 8.07 ± 1.06%, respectively, at the start of sitagliptin, decreasing significantly to 7.59 ± 1.20% (P < 0.01 vs baseline) and 7.71 ± 0.97% (P < 0.01 vs baseline) after 4 weeks and 7.09 ± 0.71% (P < 0.01 vs baseline or 4 weeks) and 7.31 ± 0.88% (P < 0.01 vs baseline or 4 weeks) after 12 weeks (Table 1). The decrease in HbA1c from baseline to 12 weeks (ΔHbA1c 0–12 weeks) was 0.79 ± 1.33% points and 0.76 ± 0.77% points, respectively. The results of an analysis that was stratified on the basis of the baseline HbA1c showed that ΔHbA1c 0–12 weeks was 1.45 ± 1.21% points in the ≥8.5% group, 0.65 ± 0.52% points in the ≥7.5% to <8.5% group, and 0.34 ± 0.44% points in the <7.5% group. ΔHbA1c 0–12 weeks was larger in patients with higher baseline HbA1c (Figure 2a).

In all patients, the monotherapy group and the combination therapy group, the blood glucose treatment target of HbA1c <7% was achieved at rates of 39.1, 44.5 and 38.2%, respectively. In all groups, the achievement rate was higher with lower baseline BMI and duration of diabetes were also significant (higher rates of patients with lower basal BMI or with shorter duration of diabetes were expected to achieve the target; Table 2). No correlation was seen for age, sex or whether the therapy was monotherapy or combination therapy.

Individual differences in the glucose-lowering effects of sitagliptin were observed in the present study, and 82 patients (11%) were unresponsive to 12 weeks’ treatment with this drug. The characteristics of the two groups (659 patients who responded and 82 patients who did not respond to sitagliptin) are shown in Table 3. The baseline BMI was significantly higher (P < 0.05) and the baseline HbA1c was significantly lower (P < 0.01) in unresponsive patients than in patients who responded to sitagliptin. A logistic regression analysis was also carried out to identify factors contributing to responsiveness to sitagliptin. The results show that baseline HbA1c (odds ratio [OR] 2.24, 95%
Data are presented as daily doses (mg/day). Before addition of sitagliptin.

Patients whose doses of sulfonylurea were reduced at the start of sitagliptin. BMI, body mass index; HbA1c, glycated hemoglobin; NS, not significant.

Table 4 | Mean doses of sulfonylureas for total patients and those whose doses of sulfonylurea were reduced at the start of sitagliptin

|                         | Before addition | 0 weeks | 12 weeks |
|-------------------------|-----------------|---------|----------|
| Total patients          |                 |         |          |
| Gliclazide (n = 49)     | 2.95 ± 1.56     | 1.68 ± 1.01 | 1.65 ± 0.98 |
| Glibenclamide (n = 13)  | 6.54 ± 1.84     | 3.65 ± 1.66 | 3.65 ± 1.80 |
| Glimepiride (n = 4)     | 7.00 ± 17.32    | 35.00 ± 8.66 | 30.00 ± 10.00 |
| Patients whose doses of sulfonylurea were reduced at the start of sitagliptin | | | |
| Gliclazide (n = 3)      | 4.46 ± 29.42    | 38.52 ± 23.18 |
| Glibenclamide (n = 63)  | 4.88 ± 2.26     | 3.77 ± 1.98 |
| Glimepiride (n = 324)   | 2.57 ± 1.57     | 2.23 ± 1.42 |

Data are presented as daily doses (mg/day). ←, values unchanged from before addition of sitagliptin.

Adverse events were generally mild to moderate. Hypoglycemia occurred in 24 patients using sulfonylureas (glimepiride 16 patients, glibenclamide 8 patients and gliclazide 0 patients). All cases were mild, and the dose of sulfonylurea drugs was decreased after the occurrence of hypoglycemia in 20 patients, but there were no cases in which the administration of sitagliptin was discontinued. Gastrointestinal adverse events included constipation (n = 3) and abdominal bloating (n = 1); dizziness (n = 4), eczema (n = 1) and edema (n = 1) were also reported. Four patients dropped out because of adverse events: constipation (n = 1), eczema (n = 1) and dizziness (n = 2). In these patients, all symptoms improved after sitagliptin was discontinued.

DISCUSSION

DPP-4 inhibitors have a novel mechanism of action, and their efficacy and safety in monotherapy or combination therapy with conventional oral diabetes drugs have not yet been reported in large numbers of patients in actual clinical settings. In the present observational study of Japanese type 2 diabetes patients receiving sitagliptin, a very large number of patients (741 patients) was enrolled. The analyses included 110 monotherapy patients and 631 combination therapy patients at 3 months after the start of sitagliptin. It was found that, in the combination therapy group, sitagliptin was used together with a wide range of 1–4 other drugs. Sulfonylurea drugs were the most common co-administered drugs, used in approximately 80% of cases. In recent results for type 2 diabetes patients being treated by diabetes specialists in Japan, sulfonylurea was used in more than 60% of patients treated with oral drugs. The accumulated results for co-administered drugs in the present study are thought to reflect this state of oral drug use in Japan. In the current patient group, HbA1c decreased significantly in both the sitagliptin monotherapy and combination therapy groups after administration for 12 weeks, whereas ΔHbA1c 0–12 weeks was 0.79 ± 1.33% points and 0.76 ± 0.77% points, respectively. The improvement in blood glucose was about the same in the two groups. The glycemic control target is a HbA1c of <7% to prevent diabetic complications, and with the administration of sitagliptin, this target was achieved in 39.1% of all 741 patients after administration for
12 weeks. In a meta-analysis of sitagliptin, the HbA1c <7% achievement rate was reported to be approximately 40%14, similar to the results in the present study. In actual clinical practice, glycemic control is attempted with various drug combinations depending on the patient’s condition and other factors, and sitagliptin was shown to be efficacious even in these various combinations.

The effect of sitagliptin is also known to vary greatly among individuals. In the present study, therefore, with the aim of identifying factors that contribute to achieving the target of HbA1c <7%, a regression analysis was carried out in which the dependent variable was whether the target HbA1c of <7% had been reached at 12 weeks, and the explanatory variables were patient background and baseline HbA1c. Three factors were found to have significant effects: (i) baseline HbA1c; (ii) baseline BMI; and (iii) duration of diabetes. Similar to earlier reports, it was also found that patients with a low baseline HbA1c were more likely to reach the target HbA1c. However, this is the first report to show that patients with low baseline BMI and patients with short duration of diabetes have a higher rate of achieving the target HbA1c. The two factors of baseline BMI and duration of diabetes were much weaker than baseline HbA1c, but they were identified as significant factors. Because these two factors have been shown to affect the hypoglycemic action of sitagliptin15,16, the hypoglycemic characteristics of sitagliptin might also affect the target achievement rate. The characteristics of the glucose-lowering effects of sitagliptin were also examined in the patients who were responsive and those who were unresponsive to sitagliptin treatment. Overall, 11% of patients were unresponsive to sitagliptin, and the baseline BMI was significantly higher and the baseline HbA1c was significantly lower in the unresponsive group than in the responsive group. The subsequent logistic regression analysis showed that these two factors, baseline BMI and HbA1c, were significantly related to responsiveness to sitagliptin therapy. Although the regulation of incretin systems and the actions of DPP-4 inhibitors have been under intensive investigation17–22, they are not fully understood. Therefore, the mechanisms by which baseline BMI and duration of diabetes contribute to the efficacy of DPP-4 inhibitors are still unknown. Interestingly, given that it has been reported that people with high BMI secrete a large amount of GLP-1, at least some of the contribution of BMI to the efficacy of DPP-4 inhibitors can be explained by differences in GLP-1 secretion17,18.

Japanese people have genetically low insulin secretion4–8, and sulfonylurea drugs are the most commonly used drugs for the treatment of type 2 diabetes in Japan. As the glycemic control of many such patients has not reached the target level, there is much interest in the efficacy of sulfonylurea drugs combined with sitagliptin. The results of the present study show that significant glycemic control improvement was achieved in patients whose glycemic control was inadequate even with therapy centered on sulfonylurea drugs. In addition, an analysis of the trends in sulfonylurea dosage showed that the sulfonylurea dose was greatly decreased compared with before the administration of sitagliptin. Thus, it was shown that good glycemic control could be achieved with lower sulfonylurea doses by administering sitagliptin. These results suggest that β-cell function is actually well activated with combined use of sulfonylurea drugs and DPP-4 inhibitors, although the effect of sitagliptin to lower glucose may also contribute to the reduced sulfonylurea doses. It is coming to be understood that incretin not only promotes the insulin release reaction in β-cells5,23, but it also stimulates the insulin secretion response through multiple actions24, such as promoting adenosine triphosphate generation in mitochondria25, and both sulfonylurea and incretin act on exchange protein directly activated by cyclic adenosine monophosphate 2A in β-cells26,27. Therefore, incretin and sulfonylurea are supposed to stimulate insulin secretion in coordinated and synergistic manners, and the present results appear to reflect these stimulatory effects of incretin and sulfonylureas on pancreatic β-cells.

Of particular note is that bodyweight was also significantly, even in the short observation period of 12 weeks when the sulfonylurea dose was decreased at the start of sitagliptin therapy. It was shown in the present study that, by reducing the dose of sulfonylurea drugs, with which bodyweight is known to increase over time28,29, and adding DPP-4 inhibitors, which have been shown to be neutral with regard to bodyweight14, bodyweight decreased in actual treatment cases. As weight gain is an undesirable effect of sulfonylurea therapy, weight loss is thought to be a positive characteristic of the combined use of sulfonylurea drugs and sitagliptin.

In an investigation of the safety of combination therapy with sitagliptin and sulfonylurea drugs, the most common adverse event was hypoglycemia, although it was mild in all cases. The dose of sulfonylurea drugs was decreased after the occurrence of hypoglycemia in 20 patients, but there were no cases in which the administration of sitagliptin was discontinued.

The present paper has presented the results of an analysis of a very large number of patients receiving sitagliptin monotherapy and combination therapy in actual clinical settings. However, because this was an observational study without control, the results of the present study could include some limitations, such as bias in selecting patients. In addition, because the observational period of the present study was 12 weeks, longer-term investigation about the durability of the efficacy and about the safety of sitagliptin treatment will be required, which is now being carried out.

The analysis showed that sitagliptin is widely used in actual treatment, and its efficacy in both monotherapy and combination therapy was shown. In particular, with the addition of sitagliptin in cases when an insufficient effect is obtained with sulfonylurea drug therapy, we can expect not only improved glycemic control, but also a reduction in sulfonylurea dose and decreased bodyweight. This is thought to be a desirable characteristic of DPP-4 inhibitor combination therapy, and it will be important to take advantage of this characteristic in diabetes therapy. These results showing the efficacy and safety of sitagliptin will surely be of value to clinical practitioners.
ACKNOWLEDGEMENTS
The authors thank the following members of Kanagawa Physicians Association who participated in this study: Dr Masaaki Miyakawa and Dr Michio Nakayama. This study was supported by a grant from the Japan Diabetes Foundation. The authors report that they have no possible conflicts of interest to declare.

REFERENCES
1. Herman GA, Stein PP, Thornberry NA, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761–767.
2. Herman GA, Stevens C, Van Dyk K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675–688.
3. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55–72.
4. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612–4619.
5. Seino Y, Fukushima M, Yabe D, GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Invest 2010; 1: 8–23.
6. Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71–77.
7. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831–835.
8. Yoshinaga H, Kosaka K. Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. Diabetes Res Clin Pract 1999; 44: 129–136.
9. Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan; second report of a cross-sectional survey of 15,652 patients. Endocr J 2010; 57: 499–507.
10. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010; 57: 383–394.
11. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010; 12: 613–622.
12. Jin Y, Kanamori A, Ito S, et al. Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. J Diabetes Invest 2012; 3: 252–258.
13. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest, 2010; 1: 212–228.
14. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594–603.
15. Maeda H, Kubota A, Tanaka Y, et al. The safety and efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e20–e22.
16. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e27–e28.
17. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717–3723.
18. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10–18.
19. Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 2010; 1: 56–59.
20. Yamane S, Harada N, Hamasaki A, et al. Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. J Diabetes Investig 2012; 3: 80–85.
21. Kubota A, Matsuba I, Saito T, et al. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. J Diabetes Invest, 2011; 2: 377–380.
22. Harada N, Hamasaki A, Yamane S, et al. Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. J Diabetes Invest 2011; 2: 193–199.
23. Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365–372.
24. Suga S, Kanno T, Nakano K, et al. GLP-1(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner. Diabetes 1997; 46: 1755–1760.
25. Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in...
diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 2011; 60: 218–226.

26. Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009; 325: 607–610.

27. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci USA 2007; 104: 19333–19338.

28. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003; 25: 799–816.

29. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006; 55: S20–S27.